KRAS and cancer: Since PI3K activation is downstream of RTK–WT RAS signaling in KRAS-mutated cancer cells [92,93] and cell cycle progression requires RTK/RAS signaling, these collateral dependent targets may represent a common mechanism for inhibiting MEK- and KRASG12C-inhibitor resistance [127].